Literature DB >> 17591851

Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.

Anne Marie Queenan1, Wenchi Shang, Malgosia Kania, Malcolm G P Page, Karen Bush.   

Abstract

The interactions of ceftobiprole with purified beta-lactamases from molecular classes A, B, C, and D were determined and compared with those of benzylpenicillin, cephaloridine, cefepime, and ceftazidime. Enzymes were selected from functional groups 1, 2a, 2b, 2be, 2d, 2e, and 3 to represent beta-lactamases from organisms within the antibacterial spectrum of ceftobiprole. Ceftobiprole was refractory to hydrolysis by the common staphylococcal PC1 beta-lactamase, the class A TEM-1 beta-lactamase, and the class C AmpC beta-lactamase but was labile to hydrolysis by class B, class D, and class A extended-spectrum beta-lactamases. Cefepime and ceftazidime followed similar patterns. In most cases, the hydrolytic stability of a substrate correlated with the MIC for the producing organism. Ceftobiprole and cefepime generally had lower MICs than ceftazidime for AmpC-producing organisms, particularly AmpC-overexpressing Enterobacter cloacae organisms. However, all three cephalosporins were hydrolyzed very slowly by AmpC cephalosporinases, suggesting that factors other than beta-lactamase stability contribute to lower ceftobiprole and cefepime MICs against many members of the family Enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591851      PMCID: PMC2043179          DOI: 10.1128/AAC.00218-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.

Authors:  Ronald N Jones; Lalitagauri M Deshpande; Alan H Mutnick; Douglas J Biedenbach
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

Review 2.  Antimicrobial resistance: the example of Staphylococcus aureus.

Authors:  Franklin D Lowy
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

3.  In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria.

Authors:  Nicolas C Issa; Mark S Rouse; Kerryl E Piper; Walter R Wilson; James M Steckelberg; Robin Patel
Journal:  Diagn Microbiol Infect Dis       Date:  2004-01       Impact factor: 2.803

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  The amino acid sequence of Staphylococcus aureus penicillinase.

Authors:  R P Ambler
Journal:  Biochem J       Date:  1975-11       Impact factor: 3.857

6.  In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters.

Authors:  R Zbinden; V Pünter; A von Graevenitz
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

7.  Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City.

Authors:  Patricia A Bradford; Simona Bratu; Carl Urban; Melissa Visalli; Noriel Mariano; David Landman; James J Rahal; Steven Brooks; Sanda Cebular; John Quale
Journal:  Clin Infect Dis       Date:  2004-06-14       Impact factor: 9.079

8.  Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2.

Authors:  Hesna Yigit; Anne Marie Queenan; J Kamile Rasheed; James W Biddle; Antonio Domenech-Sanchez; Sebastian Alberti; Karen Bush; Fred C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

9.  Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).

Authors:  Jennifer M Streit; Ronald N Jones; Helio S Sader; Thomas R Fritsche
Journal:  Int J Antimicrob Agents       Date:  2004-08       Impact factor: 5.283

10.  Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States.

Authors:  M Alvarez; J H Tran; N Chow; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

View more
  30 in total

Review 1.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

Review 2.  Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.

Authors:  Leticia I Llarrull; Jed F Fisher; Shahriar Mobashery
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

3.  New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.

Authors:  Ines Schneider; Anne Marie Queenan; Rumyana Markovska; Boyka Markova; Emma Keuleyan; Adolf Bauernfeind
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

4.  Structural insights into the anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of ceftobiprole.

Authors:  Andrew L Lovering; Michael C Gretes; Susan S Safadi; Franck Danel; Liza de Castro; Malcolm G P Page; Natalie C J Strynadka
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

5.  Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus.

Authors:  Esteban C Nannini; Martin E Stryjewski; Kavindra V Singh; Tom H Rude; G Ralph Corey; Vance G Fowler; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

Review 6.  Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 7.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

Review 8.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

9.  In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Jeffrey Fernandez; Jamese J Hilliard; Darren Abbanat; Wenyan Zhang; John L Melton; Colleen M Santoro; Robert K Flamm; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

10.  Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.

Authors:  Anne Marie Queenan; Wenchi Shang; Robert Flamm; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.